John M. Rice
Managing Director @ CincyTech
Cincinnati, United States
John M. Rice is a Series A investor at CincyTech in Cincinnati focused on Biotechnology and Health Care. John M. Rice is the Managing Director of Cincytech.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries John M. Rice invests in
Stages John M. Rice invests in
Countries John M. Rice invests in
Investment Focus
Industry
- Biotechnology 8 (47%)
- Health Care 6 (35%)
- Therapeutics 4 (24%)
- Pharmaceutical 3 (18%)
- Medical Device 2 (12%)
Stage
- Series A 5 (29%)
- Series C 5 (29%)
- Seed 3 (18%)
- Series B 3 (18%)
- Funding Round 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Invirsa
|
Invirsa is developing a unique, broad platform based on a naturally occurring small molecule (INV-102) that has demonstrated enhanced immune response to infection. INV-102 not only reduces viral infection, and potentially bacterial replication, it also reduces inflammation, while enhancing the bodies wound healing response. Invirsa'stechnology is first being developed in the ophthalmology and pulmonary space.Invirsa’s technology has the potential to be a first line therapy for common infectious diseases, whether it's the 100 million viral pulmonary infections or the 5 million infectious conjunctivitis cases that occur every year in the US alone. | $7.7M / Series B / Jun 14, 2023 | |
Genetesis
|
Genetesis is a rapidly growing medical technology company redefining the way patients with a risk of myocardial ischemia and coronary artery disease are clinically diagnosed, monitored and screened. | $17.5M / Series C / Oct 06, 2022 | |
Eikonoklastes Therapeutics
|
Eikonoklastes is advancing a new generation of tissue factor (TF) immunotherapies – therapeutics designed to target the cell surface receptor now known to be prevalent on key components of the tumor microenvironment. It has recently been discovered that certain pathological cells – but not healthy cells – including cancers with high unmet need andhigh mortality such as triple-negative breast cancer, ovarian cancer, metastatic melanoma, and a broad range of other solid tumors, express tissue factor on the surface of their cell membranes. Several other non-cancerous indications such as endometriosis also highly and selectively express tissue factor. | $2.8M / Seed / Mar 04, 2020 | |
|
Invirsa
|
Invirsa is developing a unique, broad platform based on a naturally occurring small molecule (INV-102) that has demonstrated enhanced immune response to infection. INV-102 not only reduces viral infection, and potentially bacterial replication, it also reduces inflammation, while enhancing the bodies wound healing response. Invirsa'stechnology is first being developed in the ophthalmology and pulmonary space.Invirsa’s technology has the potential to be a first line therapy for common infectious diseases, whether it's the 100 million viral pulmonary infections or the 5 million infectious conjunctivitis cases that occur every year in the US alone. | $1.8M / Series A / Dec 20, 2019 | |
|
Genetesis
|
Genetesis is a rapidly growing medical technology company redefining the way patients with a risk of myocardial ischemia and coronary artery disease are clinically diagnosed, monitored and screened. | $7.5M / Series A / Jun 05, 2018 | |
Myonexus Therapeutics
|
Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for Limb-girdle muscular dystrophy (LGMD) Types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital, a global leader in muscular dystrophy gene therapy discovery and translational research. | $2.5M / Seed / Sep 29, 2017 | |
|
Invirsa
|
Invirsa is developing a unique, broad platform based on a naturally occurring small molecule (INV-102) that has demonstrated enhanced immune response to infection. INV-102 not only reduces viral infection, and potentially bacterial replication, it also reduces inflammation, while enhancing the bodies wound healing response. Invirsa'stechnology is first being developed in the ophthalmology and pulmonary space.Invirsa’s technology has the potential to be a first line therapy for common infectious diseases, whether it's the 100 million viral pulmonary infections or the 5 million infectious conjunctivitis cases that occur every year in the US alone. | $520K / Seed / Jul 28, 2017 | |
CoLucid Pharmaceuticals
|
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders,chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina. | $37.1M / Series C / Jan 13, 2015 | |
Aerpio Pharmaceuticals
|
Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States. | $22M / Series C / Apr 23, 2014 | |
|
Aerpio Pharmaceuticals
|
Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States. | $36M / Series A / Nov 06, 2013 | |
| See all 17 investments → | |||
Co-Investors
Domain Associates
4 deals together
Pearl Street Venture Funds
4 deals together
Venture Investors
4 deals together
Rev1 Ventures
3 deals together
JobsOhio
2 deals together
JobsOhio Growth Capital Fund
2 deals together
About CincyTech
CincyTech helps to identify and transform innovation into venture-worthy, transformational human health and technology companies, primarily in southwest Ohio. Our team provides advice and capital to entrepreneurs, helps research institutions commercialize technology through startups, and catalyzes investment from individuals and institutions intoregional companies. One of the most active seed funds in the Midwest, CincyTech is supported by Ohio Third Frontier, more than two dozen foundations, corporations, municipalities and individuals as well as founding partners, Cincinnati Children’s Hospital Medical Center, the University of Cincinnati, and the Cincinnati USA Regional Chamber.
CincyTech Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
John M. Rice
Managing Director
|
|||
Ashley Keating
Chief Financial Officer
|
|||
Douglas Groh
DManaging Director
|
|||
Emma Off
President
|
|||
Jamie Easterling
Executive in Residence
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does John M. Rice invest in?
John M. Rice invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did John M. Rice last invest?
The most recent investment recorded for John M. Rice closed in Jun 2023. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
